Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency
Epilepsia · 2026
DOI: 10.1002/epi.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Maike Karnstedt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany. Hauptthemen laut MEDLINE: Memantine, Receptors, N-Methyl-D-Aspartate, Seizures, Gain of Function Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Simons Foundation, NIH-NINDS, Georgia CTSA NIH award.
Abstract (Originalsprache)
Objective
GRIN‐related disorders due to pathogenic variants in GRIN1 , GRIN2A , GRIN2B , or GRIN2D genes are associated with altered N‐methyl‐D‐aspartate receptor (NMDAR) function. Functional changes include gain (GoF) and loss of receptor function (LoF). Clinical reports describing the use of the NMDAR blocker memantine in GRIN‐related disorders show a diverse and inconsistent spectrum of treatment responses.
Methods
To evaluate clinical responses to memantine, we collected retrospective data on 34 individuals with GRIN variants, including 20 unpublished and 14 published cases. Variants were reclassified following American College of Medical Genetics and Genomics guidelines, and six in vitro functional assays were used to assess receptor function. We compared individuals with pathogenic GoF versus LoF in terms of associated clinical improvements, memantine sensitivity, and variant localization within the gene.
Results
In 19 of the 34 variants, a pathogenic likely or possible GoF of the receptor was detected. Fourteen of 19 individuals (74%) benefited from memantine, comprising improvements in behavior (71%), development (50%), and seizure frequency (39%). Individuals with either LoF or a functionally indeterminate or no effect GRIN variant (15/34 individuals) showed significantly less benefit from memantine treatment but nevertheless rare adverse events (3/15). An increased distance of the variant from the memantine binding site was associated with a clinical benefit. Significance Our retrospective observational study outlines the importance of correct classification of GRIN variants with regard to pathogenicity and functional consequence prior to applying memantine or other precision medicine approaches in clinical trials. Furthermore, the distance from a GoF variant to the memantine binding site correlated with a positive treatment response and may, at least in part, explain different degrees of therapeutic benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
- Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Center for Functional Evaluation of Rare Variants, Emory University School of Medicine, Atlanta, Georgia, USA.
- Center for Rare Developmental Disorders, Technical University of Munich, kbo Children's Center Munich, Munich, Germany.
- Division of Pediatric Neurology, Developmental Medicine, and Social Pediatrics, Department of Pediatrics, University Hospital Munich, Munich, Germany.
- Department of Pediatrics, Erasmus MC Sophia Children's Hospital, Rotterdam, the Netherlands.
ORCID-Profile: Maike Karnstedt, Riley E Perszyk, Scott J Myers, Marta Somorai, Ingo Borggraefe, Danielle C M Veenma, An-Sofie Schoonjans, Pasquale Striano, Tadeu A Fantaneanu, Steffen Syrbe, Kristen Park, Hongjie Yuan, Stephen F Traynelis, Timothy A Benke, Johannes R Lemke, Ilona Krey
Förderung
- Simons Foundation
- NIH-NINDS
- Georgia CTSA NIH award
- GRIN2B Foundation
- NIH-NICHD
Zitieren
APA
Karnstedt, M., Perszyk, R. E., Myers, S. J., McDaniels, E., Somorai, M., Borggraefe, I., Veenma, D. C. M., Schoonjans, A. S., Striano, P., Fantaneanu, T. A., Syrbe, S., Park, K., Chen, W., Yuan, H., Traynelis, S. F., Benke, T. A., Lemke, J. R., & Krey, I. (2026). Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency. Epilepsia. https://doi.org/10.1002/epi.70090
Vancouver
Karnstedt M, Perszyk RE, Myers SJ, McDaniels E, Somorai M, Borggraefe I, et al. Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency. Epilepsia. 2026. doi:10.1002/epi.70090
BibTeX
@article{Karnstedt2026,
author = {Karnstedt, Maike and Perszyk, Riley E and Myers, Scott J and McDaniels, Ellington and Somorai, Marta and Borggraefe, Ingo and Veenma, Danielle C M and Schoonjans, An-Sofie and Striano, Pasquale and Fantaneanu, Tadeu A and Syrbe, Steffen and Park, Kristen and Chen, Wenjuan and Yuan, Hongjie and Traynelis, Stephen F and Benke, Timothy A and Lemke, Johannes R and Krey, Ilona},
title = {Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70090}
}
EUVIMED